for immediate release
Tucson, AZ & Phoenix, AZ — August 15, 2025 — UGenome AI, a pioneer in genomic platforms to fuel personalized medicine, today announced a partnership with Robust Diagnostics to build out a streamlined antibody biomarker discovery service for early detection biomarker discovery. This partnership helps UGenome AI and Robust Diagnostics drive research and development toward improved clinical outcomes powered by earlier detection biomarkers.
There is a growing recognition that the immune system (Cortese et al., 2024) is a rich source of easily accessible biomarkers for early detection of chronic and neurological disease (Chatanaka et al., 2025). Many groups are exploring the role that anti-pathogen and auto-antigen immune responses (Duggan et al., 2025; Zamecnik et al., 2024) play in disease development in a number of neurological and chronic diseases, which collectively impact >60 million people worldwide.
“UGenome AI’s focus is on helping develop better treatment options and that comes directly from better diagnoses that’s why we are thrilled to partner with Robust Diagnostics who is pioneering antibody binding which is leapfrogging other early detection methods for MS. Combined with UGenome’s use of medication response and bioinformatics platform, Robust Diagnostics and UGenome AI can take a huge step forward for human health ” said Zachary Brooks, PhD, founder and CEO of UGenome AI. “We are thrilled to partner with another Arizona company to help Arizona take a leading position in biotech along with our friends at AZBio, Flinn Foundation, the Arizona Commerce Authority, the University of Arizona, Arizona State University,” and Xcellerant Ventures said Dr. Brooks.
Robust Diagnostics has developed a discovery platform for biomarker panel discovery that uses high sensitivity peptide microarrays that measure hundreds of antibodies. When this rich data is combined with proprietary machine learning (ML) powered classification, it produces a unique biomarker for disease detection. The inherent sensitivity of the immune system to changes within a person’s body combined with multi-antibody measurement produces early detection diagnostics that identify biological changes years and years before symptoms develop.
“We are excited to partner with UGenome AI to expand the reach of Robust Diagnostic’s antibody biomarker discovery services. UGenome AI has built an impressive commercial organization that provides their customers with bespoke bioinformatics services and this approach integrates perfectly with Robust Diagnostic’s drive to deliver immunological biomarker discovery to their customers in biopharma.”
#######
About UGenome AI
UGenome AI is a startup biotech company focusing on developing genomics software. UGenome AI is advancing genomics analysis and helping patients receive personalized care, faster. Our products bioinformatics and pharmacogenomics tools to help patients receive personalized treatments within weeks, not years. For more information, please visit www.ugenome.io.
About Robust Diagnostics
Robust Diagnostics is a discovery services company that provides antibody biomarker discovery and targeting peptide discovery services to customers in the biopharmaceutical industry. Their most advanced internal diagnostic program is developing a blood test for early detection of multiple sclerosis, a neurodegenerative disease that affects over 1 million people in the US. To learn more, please visit www.robustdx.com.
Contacts
For UGenome AI Inquiries:
Zachary Brooks
[email protected]
For Robust Diagnostics Inquiries.
Chris Diehnelt
[email protected]
For Media:
Emma Bardin
[email protected]